| Literature DB >> 31935247 |
Jacob A Yaffe1, Yair Zlotnik2, Gal Ifergane2, Shelly Levy-Tzedek3,4,5.
Abstract
People with Parkinson's disease have been shown to have difficulty switching between movement plans. In the great majority of studies, the need to switch between tasks was made explicitly. Here, we tested whether people with Parkinson's disease, taking their normal medication, have difficulty switching between implicitly specified tasks. We further examined whether this switch is performed predictively or reactively. Twenty five people with Parkinson's disease continuously increased or decreased the frequency of their arm movements, inducing an abrupt-but unaware-switch between rhythmic movements (at high frequencies) and discrete movements (at low frequencies). We tested whether that precipitous change was performed reactively or predictively. We found that 56% of participants predictively switched between the two movement types. The ability of people with Parkinson's disease, taking their regular medication, to predictively control their movements on implicit tasks is thus preserved.Entities:
Year: 2020 PMID: 31935247 PMCID: PMC6959575 DOI: 10.1371/journal.pone.0227555
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Examples of velocity traces, from the current experiment, recorded during a discrete (A) and during a rhythmic (B) movement performed by participant #1. (C) The participant places his arm on the armrest, below an opaque cover. He uses the movements of his forearm to control a cursor on a phase plane, displayed on a computer screen (D) example of a training ellipse ‘C’ from the current experiment, shown in black on a phase plane, along with the movement trace of participant # 1 (in green).
Fig 2Testing ellipses.
The ellipse size was continuously changed during the testing session: the required amplitude (x-axis) remained constant, while the required speed gradually increased or decreased. Shown in black is the ellipse that requires low-frequency forearm movement, and in light-gray is the ellipse that requires high-frequency movement.
Baseline data and results for the study participants.
| ID | Age | Gender | UPDRS motor score | MMSE | Years since diagnosis | PD dominance | Dominant hand | Medication | Switch pattern |
|---|---|---|---|---|---|---|---|---|---|
| 01 | 79 | M | 13 | 29 | 2 | LT | RT | Carbidopa-Levodopa | PH |
| 02 | 72 | M | 15 | 27 | 1 | None | RT | Rasagiline, Carbidopa-Levodopa | PH |
| 03 | 68 | M | 12 | 28 | 2 | RT | RT | Not on medications by choice | RH |
| 04 | 59 | F | 24 | 30 | 3 | LT | RT | Rasagiline, Carbidopa-Levodopa Ropinirole | PH |
| 05 | 76 | M | 12 | 30 | 3 | LT | RT | Carbidopa-Levodopa | RH |
| 06 | 78 | M | 11 | 27 | 5 | RT | LT | Carbidopa-Levodopa | RH |
| 07 | 71 | F | 16 | 30 | 8 | LT | RT | Rasagiline, Carbidopa-Levodopa | RH |
| 08 | 69 | F | 11 | 29 | 2 | LT | RT | Rasagiline | RH |
| 09 | 54 | M | 9 | 28 | 2 | LT | RT | Amantadine, Ropinirole | RH |
| 10 | 65 | M | 16 | 28 | 5 | RT | RT | Amantadine, Rasagiline, Carbidopa-Levodopa, Ropinirole | PH |
| 11 | 63 | M | 9 | 28 | 1 | None | RT | Rasagiline, Ropinirole | RH |
| 12 | 70 | F | 21 | 30 | 2 | None | LT | Rasagiline, Carbidopa-Levodopa | RH |
| 13 | 70 | M | 13 | 29 | 0 | LT | RT | Rasagiline, Procyclidine | EQ |
| 14 | 66 | M | 15 | 29 | 3 | RT | RT | Carbidopa-Lavodopa-Entacapone | RH |
| 15 | 51 | M | 13 | 27 | 1 | None | RT | Amantadine, Rasagiline, Carbidopa-Levodopa | RH |
| 16 | 53 | F | 22 | 29 | 7 | LT | RT | Carbidopa-Lavodopa-Entacapone | RH |
| 17 | 67 | M | 26 | 30 | 2 | LT | RT | Rasagiline, Carbidopa-Levodopa | PH |
| 18 | 70 | M | 39 | 28 | 1 | RT | RT | Amantadine | PH |
| 19 | 66 | F | 18 | 30 | 3 | RT | RT | Rasagiline, Carbidopa-Levodopa | PH |
| 20 | 53 | M | 27 | 29 | 1 | LT | RT | Rasagiline, Ropinirole | RH |
| 21 | 64 | M | 49 | 29 | 8 | Both | RT | Amantadine, Rasagiline, Carbidopa-Levodopa- Entacapone, Biperiden | RH |
| 22 | 81 | M | 14 | 29 | 1 | RT | RT | Carbidopa-Levodopa | PH |
| 23 | 59 | M | 9 | 25 | 4 | LT | RT | Rasagiline, Carbidopa-Levodopa, Carbidopa-Levodopa- Entacapone | PH |
| 24 | 76 | M | 46 | 27 | 2 | RT | RT | Amantadine, Rasagiline, Carbidopa-Levodopa- Entacapone | RH |
| 25 | 70 | F | 24 | 26 | 5 | RT | RT | Amantadine, Rasagiline, Carbidopa-Levodopa, Ropinirole | PH |
* The abbreviations here correspond to those in Fig 3: RH indicates a reverse hysteresis, PH indicates a positive hysteresis, and EQ implies there was effectively no difference between the FsINC and FsDEC.
Fig 3Switch-point frequency (Fs).
Average values for Fs on the decreasing-frequency trials (DEC) are marked by a white circle, and those on the increasing-frequency trials (INC) are marked by a black circle. For each pair of INC-DEC results, two letters marked at the top indicate whether this pair shows a reverse-hysteresis pattern (RH), a positive hysteresis pattern (PH), or the switch point frequency is equal at the INC and the DEC trials (EQ). For the sake of clarity, the results are grouped by pattern (RH/EQ/PH), with the participant number on the x-axis corresponding to the chronological order in which participants were tested. Error bars represent standard error.
Fig 4Sample velocity profile on an decreasing-frequency (DEC) trial.
Shown here is the velocity profile from an decreasing-frequency trial of participant # 21, the only participant in this study who had a confirmed diagnosis of FOG. A thicker line is used to outline the discrete portion of the trial. This graph demonstrates the percipitous switching that occurs between the rhythmic and the discrete movement types during a trial (shown here is a 30-sec excerpt from a 66.5-sec trial).